This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Korting, H. C.
Right arrow Articles by Hube, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Korting, H. C.
Right arrow Articles by Hube, B.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 1999, p. 2038-2042, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Effects of the Human Immunodeficiency Virus (HIV) Proteinase Inhibitors Saquinavir and Indinavir on In Vitro Activities of Secreted Aspartyl Proteinases of Candida albicans Isolates from HIV-Infected Patients

Hans C. Korting,1 Martin Schaller,1,* Gabriele Eder,1 Gerald Hamm,2 Ursula Böhmer,1 and Bernhard Hube3

Department of Dermatology1 and Department of Parodontology,2 Ludwig-Maximilians-University, Munich, and Institute for General Botany, Applied Molecular Biology III, University of Hamburg, Hamburg,3 Germany

Received 16 November 1998/Returned for modification 20 January 1999/Accepted 7 May 1999

The effects of therapeutically relevant concentrations of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on the in vitro proteinase activity of Candida albicans were investigated with isolates from HIV-infected and uninfected patients with oral candidiasis. After exposure to the HIV proteinase inhibitors, proteinase activity was significantly reduced in a dose-dependent manner. These inhibitory effects, which were similar to that of pepstatin A, and the reduced virulence phenotype in experimental candidiasis after application of saquinavir indicate the usefulness of these HIV proteinase inhibitors as potential anticandidal agents.

* Corresponding author. Mailing address: Dermatologische Klinik und Poliklinik der Ludwig-Maximilians-Universität München, Frauenlobstr. 9-11, D-80337 München, Germany. Phone: 49 89 5160 6151. Fax: 49 89 5160 6007.

Antimicrobial Agents and Chemotherapy, August 1999, p. 2038-2042, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Staib, P., Lermann, U., Bla -Warmuth, J., Degel, B., Wurzner, R., Monod, M., Schirmeister, T., Morschhauser, J. (2008). Tetracycline-Inducible Expression of Individual Secreted Aspartic Proteases in Candida albicans Allows Isoenzyme-Specific Inhibitor Screening. Antimicrob. Agents Chemother. 52: 146-156 [Abstract] [Full Text]  
  • Backman, D., Monod, M., Danielson, U. H. (2006). Biosensor-Based Screening and Characterization of HIV-1 Inhibitor Interactions with Sap 1, Sap 2, and Sap 3 from Candida albicans. J Biomol Screen 11: 165-175 [Abstract]  
  • Menotti, J., Santillana-Hayat, M., Cassinat, B., Sarfati, C., Derouin, F., Molina, J.-M. (2005). Inhibitory Activity of Human Immunodeficiency Virus Aspartyl Protease Inhibitors against Encephalitozoon intestinalis Evaluated by Cell Culture-Quantitative PCR Assay. Antimicrob. Agents Chemother. 49: 2362-2366 [Abstract] [Full Text]  
  • de Repentigny, L., Lewandowski, D., Jolicoeur, P. (2004). Immunopathogenesis of Oropharyngeal Candidiasis in Human Immunodeficiency Virus Infection. Clin. Microbiol. Rev. 17: 729-759 [Abstract] [Full Text]  
  • Naglik, J. R., Challacombe, S. J., Hube, B. (2003). Candida albicans Secreted Aspartyl Proteinases in Virulence and Pathogenesis. Microbiol. Mol. Biol. Rev. 67: 400-428 [Abstract] [Full Text]  
  • Atzori, C., Clerici, M., Trabattoni, D., Fantoni, G., Valerio, A., Tronconi, E., Cargnel, A. (2003). Assessment of immune reconstitution to Pneumocystis carinii in HIV-1 patients under different highly active antiretroviral therapy regimens. J Antimicrob Chemother 52: 276-281 [Abstract] [Full Text]  
  • Schaller, M., Krnjaic, N., Niewerth, M., Hamm, G., Hube, B., Korting, H. C. (2003). Effect of antimycotic agents on the activity of aspartyl proteinases secreted by Candida albicans. J Med Microbiol 52: 247-249 [Abstract] [Full Text]  
  • Barchiesi, F., Maracci, M., Radi, B., Arzeni, D., Baldassarri, I., Giacometti, A., Scalise, G. (2002). Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother 50: 999-1002 [Abstract] [Full Text]  
  • Martinez, M., Lopez-Ribot, J. L., Kirkpatrick, W. R., Bachmann, S. P., Perea, S., Ruesga, M. T., Patterson, T. F. (2002). Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J Antimicrob Chemother 49: 515-524 [Abstract] [Full Text]  
  • Hube, B., Naglik, J. (2001). Candida albicans proteinases: resolving the mystery of a gene family. Microbiology 147: 1997-2005 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»